Pharmacology of Heparin

Introduction/Overview

Heparin represents a cornerstone of anticoagulant therapy, belonging to the class of glycosaminoglycans. Its discovery in 1916 by Jay McLean and subsequent clinical introduction revolutionized the management of thrombotic disorders. As a naturally occurring substance, heparin’s primary pharmacological role is to accelerate the inhibition of coagulation proteases, thereby preventing the formation and extension of pathological blood clots. The clinical importance of heparin is profound, as it is utilized across a broad spectrum of medical and surgical conditions where rapid anticoagulation is required, including acute coronary syndromes, venous thromboembolism, and during cardiopulmonary bypass procedures. Unlike oral anticoagulants, heparin’s parenteral administration and immediate onset of action make it indispensable in acute care settings.

Learning Objectives

• Describe the chemical nature and classification of heparin and its derivatives, distinguishing between unfractionated heparin and low molecular weight heparins.
• Explain the detailed molecular mechanism by which heparin potentiates antithrombin III to inhibit key coagulation factors, primarily thrombin and factor Xa.
• Analyze the pharmacokinetic properties of heparin, including its absorption, distribution, metabolism, and elimination, and relate these to dosing strategies and monitoring requirements.
• Identify the major therapeutic indications for heparin therapy, along with its common and serious adverse effects, particularly heparin-induced thrombocytopenia.
• Apply knowledge of drug interactions, contraindications, and special population considerations to develop safe and effective heparin treatment plans.

Classification

Heparins are classified based on their molecular weight and method of preparation, which directly influence their pharmacological profile.

Chemical and Pharmacological Classification

Heparins are sulfated glycosaminoglycans composed of repeating disaccharide units of D-glucosamine and uronic acid (either L-iduronic or D-glucuronic acid). The anticoagulant activity is dependent on a unique pentasaccharide sequence that binds with high affinity to antithrombin III. From a pharmacological standpoint, heparins are categorized as indirect thrombin inhibitors.

Major Categories

• Unfractionated Heparin (UFH): This is a heterogeneous mixture of polysaccharide chains with molecular weights ranging from 3,000 to 30,000 Daltons, with a mean of approximately 15,000 Daltons. It is derived from porcine intestinal mucosa or bovine lung. UFH exhibits anti-factor IIa (thrombin) and anti-factor Xa activity, but its effect is unpredictable due to variable binding to plasma proteins and cells, necessitating close laboratory monitoring.
• Low Molecular Weight Heparins (LMWHs): These are produced by the controlled chemical or enzymatic depolymerization of UFH, resulting in shorter chains with mean molecular weights between 4,000 and 5,000 Daltons. Examples include enoxaparin, dalteparin, and tinzaparin. LMWHs have a higher ratio of anti-factor Xa to anti-factor IIa activity (typically 2:1 to 4:1) compared to UFH (1:1). Their more predictable pharmacokinetic profile allows for weight-based dosing without routine laboratory monitoring in most patients.
• Fondaparinux: A synthetic pentasaccharide that represents the minimal antithrombin-binding sequence found in heparin and LMWH. It selectively inhibits factor Xa without any direct anti-thrombin activity. While not a heparin molecule per se, it is often discussed within this therapeutic class due to its shared mechanism via antithrombin.

Mechanism of Action

The anticoagulant effect of heparin is mediated through an indirect mechanism that requires a plasma cofactor, antithrombin III (AT).

Molecular and Cellular Mechanisms

Antithrombin III is a serine protease inhibitor (serpin) that inactivates several enzymes in the coagulation cascade, most importantly thrombin (factor IIa) and factor Xa. In its native state, AT inhibits these proteases slowly. Heparin acts as a catalytic template that dramatically accelerates this reaction by at least 1000-fold. The critical interaction occurs when a specific pentasaccharide sequence within the heparin chain binds with high affinity to a lysine site on the AT molecule. This binding induces a conformational change in the reactive center loop of AT, making it more accessible to the target protease.

For thrombin inhibition, a ternary complex must form. Heparin must bind simultaneously to both AT and thrombin, which requires a chain length of at least 18 saccharide units (approximately 5,400 Daltons). This bridging function explains why UFH, with its longer chains, is a potent inhibitor of both factor Xa and thrombin. In contrast, the shorter chains of LMWHs and fondaparinux can bind to and activate AT but are generally too short to bridge to thrombin. Consequently, they primarily exert anti-factor Xa activity. Inhibition of factor Xa only requires the pentasaccharide sequence to bind AT, as factor Xa inhibition occurs without the need for heparin to bind the protease directly.

By inhibiting thrombin, heparin prevents fibrin formation, inhibits thrombin-induced activation of platelets and factors V and VIII, and attenuates the amplification of the coagulation cascade. Inhibition of factor Xa blocks the conversion of prothrombin to thrombin, suppressing the propagation phase of coagulation.

Additional Pharmacodynamic Effects

Beyond its primary anticoagulant action, heparin binds to a variety of other proteins and cells, which contributes to its complex pharmacokinetics and some side effects. It binds to endothelial cells, macrophages, and platelet factor 4 (PF4). High doses of heparin may have a mild anti-inflammatory effect, potentially by binding to and neutralizing cationic proteins. Heparin also activates lipoprotein lipase, leading to a transient increase in plasma free fatty acids, though this effect has limited clinical significance.

Pharmacokinetics

The pharmacokinetics of heparin are complex, nonlinear, and highly variable, particularly for UFH, due to extensive binding to plasma proteins and cellular components.

Absorption

Heparin is not absorbed from the gastrointestinal tract because it is a large, highly polar molecule. Therefore, it must be administered parenterally. UFH is typically given as an intravenous bolus or continuous infusion for immediate and controllable effects, or as a subcutaneous injection for prophylactic indications. Subcutaneous absorption of UFH is variable and bioavailability is incomplete, ranging from 10% to 40%, due to binding at the injection site. LMWHs have superior and more consistent subcutaneous bioavailability, approaching 90% for agents like enoxaparin, which allows for reliable once- or twice-daily dosing.

Distribution

Following intravenous administration, UFH distributes mainly within the intravascular compartment. It binds extensively to plasma proteins (including acute phase reactants like histidine-rich glycoprotein and PF4), endothelial cells, and macrophages. This extensive and variable protein binding is a primary reason for the unpredictable anticoagulant response and the need for monitoring. The volume of distribution of UFH is small, approximately equal to plasma volume (0.05–0.07 L/kg). LMWHs exhibit less plasma protein binding, contributing to their more predictable dose-response relationship.

Metabolism and Excretion

Heparin undergoes a combination of saturable and non-saturable clearance pathways. The saturable, zero-order pathway involves rapid binding to endothelial cells and macrophages, where it is depolymerized. The non-saturable, first-order pathway is renal elimination of smaller fragments. At low doses, the saturable cellular mechanism predominates, leading to a dose-dependent half-life. At therapeutic doses, both pathways operate, and the half-life becomes more consistent but remains dose-dependent, increasing from approximately 30 minutes with a 25 U/kg IV bolus to 60 minutes with a 100 U/kg bolus. Renal clearance becomes more significant at higher doses and for the smaller fragments of LMWH. Consequently, LMWHs have longer and more predictable half-lives (3–6 hours after subcutaneous injection) and are primarily renally excreted. Accumulation of LMWHs can occur in patients with significant renal impairment.

Half-life and Dosing Considerations

The variable pharmacokinetics of UFH necessitate individualized dosing guided by laboratory monitoring, typically the activated partial thromboplastin time (aPTT). The therapeutic target is usually an aPTT ratio of 1.5 to 2.5 times the control value. Weight-based nomograms (e.g., an initial IV bolus of 80 U/kg followed by a continuous infusion of 18 U/kg/hour) are standard for improving the efficiency of achieving therapeutic anticoagulation. In contrast, LMWHs are dosed based on body weight (e.g., enoxaparin 1 mg/kg every 12 hours or 1.5 mg/kg daily for treatment of venous thromboembolism), and routine monitoring of anti-factor Xa levels is not required for most patients, except in special populations like pregnant women, obese patients, or those with renal failure.

Therapeutic Uses/Clinical Applications

Heparin is employed in a wide array of clinical scenarios where rapid anticoagulation is necessary to treat or prevent thrombotic events.

Approved Indications

• Treatment of Venous Thromboembolism (VTE): Heparin is the initial therapy for acute deep vein thrombosis (DVT) and pulmonary embolism (PE). It rapidly halts thrombus extension, allowing the body’s endogenous fibrinolytic system to begin resolving the clot. A 5- to 10-day overlap with a vitamin K antagonist (e.g., warfarin) is standard, or until the international normalized ratio (INR) is therapeutic for at least 24 hours. LMWHs are often preferred for DVT treatment due to their outpatient dosing potential.
• Acute Coronary Syndromes (ACS): In unstable angina and non-ST-elevation myocardial infarction (NSTEMI), heparin (UFH or LMWH) is used with antiplatelet agents to prevent coronary artery thrombosis. In ST-elevation myocardial infarction (STEMI), it is used as adjunctive therapy with fibrinolytic agents or during percutaneous coronary intervention (PCI).
• Prophylaxis of Venous Thromboembolism: Low-dose subcutaneous UFH or LMWH is widely used to prevent DVT in high-risk patients, such as those undergoing major surgery (especially orthopedic), immobilized medical patients, and during pregnancy in women with a history of thrombosis.
• Cardiopulmonary Bypass and Vascular Surgery: High-dose UFH is mandatory to prevent clot formation in the extracorporeal circuit during cardiac surgery and other procedures requiring temporary circulatory arrest.
• Disseminated Intravascular Coagulation (DIC): Heparin may be used in selected cases of DIC, particularly when thrombosis predominates over bleeding, such as in cases associated with malignancy or purpura fulminans.
• Atrial Fibrillation: Heparin is used for rapid anticoagulation in patients with atrial fibrillation at high risk for stroke, often as a “bridge” during initiation or interruption of oral anticoagulant therapy.

Off-Label Uses

Heparin is sometimes used in other clinical contexts. It is employed in the maintenance of patency for intravenous and arterial lines. Heparin flushes are common, though their efficacy compared to saline flushes is debated. In selected cases of heparin resistance, where standard doses fail to achieve a therapeutic aPTT, antithrombin III concentrate may be administered. Heparin is also used in certain forms of vasculitis and in the prevention of clotting during continuous renal replacement therapy (CRRT).

Adverse Effects

While highly effective, heparin therapy is associated with several significant adverse effects that require vigilant monitoring.

Common Side Effects

• Bleeding: The most frequent complication, ranging from minor bruising at injection sites to major, life-threatening hemorrhage (e.g., intracranial, retroperitoneal). Risk factors include concomitant use of other antithrombotic agents, recent surgery, trauma, and underlying hemostatic defects.
• Heparin-Induced Thrombocytopenia (HIT): This is a serious, immune-mediated adverse reaction. Type I HIT is a mild, non-immune form with a transient drop in platelet count occurring within the first two days of therapy. Type II HIT is the clinically significant form, typically occurring 5 to 10 days after initiation (sooner if there was recent heparin exposure). It is caused by antibodies, usually IgG, directed against complexes of heparin and platelet factor 4. These immune complexes activate platelets via their FcγRIIa receptors, leading to profound thrombocytopenia and a paradoxical prothrombotic state. Arterial and venous thrombosis (HITT) occurs in up to 50% of patients, with significant morbidity and mortality. Management requires immediate cessation of all heparin products and initiation of a non-heparin anticoagulant (e.g., argatroban, bivalirudin, fondaparinux).
• Elevated Liver Enzymes: Asymptomatic increases in serum transaminases are commonly observed with heparin and LMWH use, typically resolving even with continued therapy. This effect is not indicative of hepatocellular injury.
• Osteoporosis: With long-term use (greater than one month), particularly in pregnancy, heparin can cause bone density loss and vertebral fractures. This is thought to result from heparin binding to osteoblasts, inhibiting bone formation, and increasing osteoclast activity.
• Local Reactions: Pain, erythema, and hematoma at subcutaneous injection sites are common. Skin necrosis is a rare but severe local reaction.
• Hyperkalemia: Heparin can suppress aldosterone synthesis, potentially leading to elevated serum potassium levels, particularly in patients with diabetes or renal impairment.

Serious/Rare Adverse Reactions

Anaphylactic reactions, though rare, can occur, especially with bovine lung-derived heparin. Spontaneous spinal or epidural hematoma is a catastrophic complication associated with neuraxial anesthesia or lumbar puncture in patients receiving anticoagulant therapy, particularly with LMWH. This risk necessitates strict timing guidelines between dose administration and needle placement/catheter removal.

Drug Interactions

Heparin’s primary interactions involve pharmacodynamic synergism with other agents that affect hemostasis, increasing the risk of bleeding.

Major Drug-Drug Interactions

• Antiplatelet Agents: Concomitant use with aspirin, P2Y₁₂ inhibitors (e.g., clopidogrel), or glycoprotein IIb/IIIa inhibitors (e.g., abciximab) significantly increases bleeding risk. This combination is often used intentionally in acute coronary syndromes but requires careful monitoring.
• Oral Anticoagulants: Concurrent use with warfarin or direct oral anticoagulants (DOACs) markedly elevates bleeding risk. This overlap is managed carefully during the transition period from heparin to oral therapy.
• Thrombolytic Agents: Drugs like alteplase or streptokinase used in conjunction with heparin for conditions like acute myocardial infarction or massive pulmonary embolism substantially increase the risk of hemorrhage.
• Other Drugs Affecting Hemostasis: Nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), and certain antibiotics (e.g., high-dose penicillins) may impair platelet function and compound bleeding risk.
• Nitroglycerin: Intravenous nitroglycerin has been reported to reduce the anticoagulant effect of UFH, possibly by altering its binding to antithrombin III, potentially necessitating higher heparin infusion rates and more frequent aPTT monitoring.
• Digitalis, Tetracyclines, Nicotine, Antihistamines: These agents may partially counteract the anticoagulant effect of heparin, though the clinical significance is variable.

Contraindications

Absolute contraindications to heparin therapy include active major bleeding, severe uncontrolled hypertension, known hypersensitivity to heparin (or porcine products), and documented or suspected HIT (for all heparin products, including LMWH). Relative contraindications require a careful risk-benefit assessment and include recent major surgery (e.g., neurosurgery, eye surgery), history of heparin-induced thrombocytopenia, severe thrombocytopenia, suspected intracranial hemorrhage, and conditions with a high risk of uncontrollable bleeding (e.g., peptic ulcer disease, hemorrhagic stroke).

Special Considerations

The use of heparin requires careful adjustment and monitoring in specific patient populations due to altered pharmacokinetics, pharmacodynamics, or safety profiles.

Use in Pregnancy and Lactation

Heparin and LMWHs are the anticoagulants of choice during pregnancy because they do not cross the placenta and are not associated with teratogenicity. Warfarin is contraindicated, particularly in the first trimester. UFH and LMWH are considered safe, though long-term UFH use is associated with a higher risk of osteoporosis. LMWHs are generally preferred due to their more predictable effect and lower risk of HIT and osteoporosis. Neither UFH nor LMWH is secreted into breast milk in significant amounts, making them compatible with breastfeeding.

Pediatric Considerations

Dosing in neonates, infants, and children differs from adults due to developmental differences in pharmacokinetics. Neonates and infants often require higher doses per kilogram of body weight for UFH due to a larger volume of distribution and potentially reduced levels of antithrombin III. Monitoring with aPTT is essential, and age-specific therapeutic ranges may be necessary. LMWHs are also used in children, with dosing based on body weight and monitoring via anti-factor Xa levels (target peak 0.5–1.0 U/mL for twice-daily dosing).

Geriatric Considerations

Elderly patients are at increased risk for both thrombotic events and bleeding complications. Age-related declines in renal function can lead to accumulation of LMWHs, increasing bleeding risk. Dosing of LMWHs often requires adjustment based on renal function (creatinine clearance), and careful assessment of bleeding risk factors (e.g., falls, concomitant medications) is mandatory. The use of UFH may be preferred in some elderly patients with severe renal impairment due to its non-renal clearance pathways.

Renal and Hepatic Impairment

Renal Impairment: This has a significant impact on LMWH and fondaparinux pharmacokinetics, as they are primarily renally eliminated. Accumulation increases the risk of bleeding. Dose reduction or increased dosing intervals are recommended for LMWHs when creatinine clearance falls below 30 mL/min. UFH, with its mixed clearance, is often the preferred agent in severe renal failure, though it still requires careful monitoring. Anti-factor Xa level monitoring is advised for LMWH use in renal impairment.

Hepatic Impairment: Liver disease can be complex, as it may be associated with both a prothrombotic state and coagulopathy. Reduced synthesis of clotting factors and antithrombin III can alter the response to heparin. Patients with liver disease may be more sensitive to heparin’s effects, and bleeding risk is elevated. Close monitoring of both anticoagulant effect (aPTT) and standard coagulation tests (PT/INR) is necessary.

Obesity

In obese patients, dosing based on total body weight is recommended for both UFH (for VTE treatment) and LMWHs, as distribution appears to correlate with weight. However, there may be an increased risk of accumulation with LMWHs. For very high body weight (e.g., > 150 kg), some protocols cap the dose or recommend monitoring with anti-factor Xa levels.

Summary/Key Points

• Heparin is a parenteral anticoagulant that acts indirectly by binding to and potentiating antithrombin III, leading to the rapid inactivation of thrombin and factor Xa.
• Unfractionated heparin is a heterogeneous mixture requiring frequent monitoring via aPTT due to unpredictable pharmacokinetics, while low molecular weight heparins have more predictable effects allowing for weight-based dosing without routine monitoring.
• The primary clinical applications include the treatment and prevention of venous thromboembolism, management of acute coronary syndromes, and anticoagulation during cardiopulmonary bypass.
• The most serious adverse effect is heparin-induced thrombocytopenia (HIT), an immune-mediated condition characterized by thrombocytopenia and a paradoxical increase in thrombotic risk, necessitating immediate cessation of heparin.
• Major bleeding is the most common complication. Significant drug interactions occur primarily with other agents affecting hemostasis, increasing bleeding risk.
• Heparin and LMWHs are the anticoagulants of choice in pregnancy. Dose adjustments are critical in patients with renal impairment, particularly for LMWHs, and in pediatric and geriatric populations.

Clinical Pearls

• When managing a sudden decrease in platelet count (typically >50% from baseline) in a patient receiving heparin, HIT must be considered and evaluated using a clinical scoring system (e.g., 4Ts score) and laboratory testing for HIT antibodies.
• For major bleeding on therapeutic heparin, protamine sulfate can rapidly reverse the anticoagulant effect of UFH and partially reverse that of LMWH (more effective for anti-IIa activity than anti-Xa activity).
• In patients with severe renal impairment (CrCl < 30 mL/min), UFH may be a safer choice than LMWH due to its non-renal clearance pathways, despite the need for monitoring.
• To minimize the risk of spinal hematoma, neuraxial procedures should be timed appropriately relative to LMWH dosing (e.g., at least 12 hours after a prophylactic dose).
• Remember that a normal aPTT does not rule out the presence of therapeutic anti-factor Xa levels in patients on LMWH; specific anti-Xa assays are required if monitoring is needed.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.